Epstein-Barr virus glycoprotein gp42 (gp42)

Epstein-Barr virus glycoprotein gp42 is a critical component of the viral entry machinery, specifically required for the infection of B lymphocytes. It functions as part of a tripartite complex with glycoproteins gH and gL, where gp42 acts as the receptor-binding protein that recognizes HLA class II molecules (such as HLA-DR) on the host cell surface. This binding event triggers a conformational change in the gH/gL complex, which subsequently activates the fusion protein gB to mediate the merging of the viral envelope with the host cell membrane. Interestingly, gp42 serves as a molecular switch; while it is essential for B-cell entry, its presence actually inhibits the infection of epithelial cells, which require only the gH/gL complex. Given its indispensable role in B-cell infection, gp42 is a primary target for the development of prophylactic vaccines and therapeutic monoclonal antibodies. Research has shown that neutralizing antibodies directed against the HLA-binding site of gp42 can effectively prevent EBV infection in preclinical models. Targeting gp42 is particularly relevant for preventing EBV-associated malignancies and autoimmune conditions like multiple sclerosis, where B-cell infection plays a central role in pathogenesis. Current therapeutic strategies focus on using soluble gp42 or nanoparticle-based gp42 vaccines to elicit a robust immune response that blocks the virus before it can establish latency in the B-cell reservoir.

Other names

BZLF2EBV gp42Glycoprotein 42Epstein-Barr virus BZLF2 gene product

Neutralizing antibodies target gp42 to block its interaction with HLA class II molecules on the surface of B cells, thereby preventing the triggering of the gH/gL/gp42 fusion complex and inhibiting viral entry.